The Foundation has designated the University Medical Center Utrecht in the Netherlands as the latest Focused Ultrasound Center of Excellence. Please join us for a virtual opening event on Tuesday, January 19, at 9:00 am Eastern to learn about this dynamic center’s diverse research projects.
A novel pivotal trial validating the use of focused ultrasound to treat the cardinal features of Parkinson’s disease has been published in the New England Journal of Medicine.
Today at 1:00 pm Eastern, women leaders in focused ultrasound will reflect on the documentary, their experiences, and how to bring more equity and diversity to the field. All are encouraged to attend.
The Eddie and Jo Allison Smith Foundation Fund for Focused Ultrasound Treatment of Neurodegenerative Disorders will support research for disorders such as Alzheimer’s disease, Parkinson’s, ALS, and Huntington’s.
In a webinar from the Foundation and the American Institute of Ultrasound in Medicine, Suzanne LeBlang, MD, discussed the noninvasive treatment and compared MR- and US-guided procedures.
A new clinical trial is investigating using focused ultrasound to treat glioblastoma by activating a drug to cause tumor cell death. The trial is being conducted at the Ivy Brain Tumor Center within the Barrow Neurological Institute in Phoenix, Arizona.
Patients who are interested in learning more should contact (602) 406-8605 or .
Hugo Embert, EDAP’s Chief Marketing Officer, and two physicians discuss the impact of the CPT® Category I code on insurance coverage for focused ultrasound treatment of the prostate.
Marc Oczachowski, EDAP’s Chairman and CEO, and two physicians discuss their efforts to keep patients safe during focused ultrasound prostate procedures.
The first patient has been treated in a new phase I/II clinical trial for patients with recurrent glioblastoma. Researchers at Northwestern University are testing CarThera’s SonoCloud-9 device in combination with chemotherapy.
A focused ultrasound review paper is the cover story of Nature Reviews Neurology’s January 2021 issue. The comprehensive brain treatment overview by a team in Toronto was originally published online in October 2020.
The Centers for Medicare and Medicaid Services has issued a final rule that provides immediate national Medicare coverage for four years for any new device or diagnostic designated as a breakthrough technology and approved by the US FDA.
The two companies have collaborated to develop compatibility between Philips’ advanced MR systems and Insightec’s Exablate Neuro platform to improve the patient and staff experience, enhance health outcomes, and lower the cost of care.
The US Food and Drug Administration introduced a new Safer Technologies Program (STeP) designed to facilitate patient access to innovative medical therapies.
The agreement will enable Profound to interface its TULSA-PRO® prostate system with certain GE Healthcare MRI scanners, thereby expanding access to both patients and physicians around the world.
The International Society for Therapeutic Ultrasound will host Bradley Treeby, Professor of Biomedical Ultrasound at the University College London, for its first webinar of the new year.
